Cargando…
Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
The changes in the severe acute respiratory syndrome coronavirus 2 and the tapering of immunity after vaccination have propelled the need for a booster dose vaccine. We aim to evaluate B and T cell immunogenicity and reactogenicity of mRNA-1273 COVID-19 vaccine (100 µg) as a third booster dose after...
Autores principales: | Tangsathapornpong, Auchara, Nanthapisal, Sira, Pontan, Kanassanan, Bunjoungmanee, Pornumpa, Neamkul, Yamonbhorn, Boonyarangkul, Arthit, Wanpen, Supattra, Fukpho, Waraphon, Jitpokasem, Sumana, Tharabenjasin, Phuntila, Jaru-Ampornpan, Peera |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053262/ https://www.ncbi.nlm.nih.gov/pubmed/36992137 http://dx.doi.org/10.3390/vaccines11030553 |
Ejemplares similares
-
A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines
por: Nanthapisal, Sira, et al.
Publicado: (2022) -
Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster
por: Chantasrisawad, Napaporn, et al.
Publicado: (2022) -
Prevalence, risk factors, and vaccine effectiveness of COVID-19 infection in thai children, adolescents, and young adults in the omicron era
por: Chaiyakulsil, Chanapai, et al.
Publicado: (2023) -
Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?
por: Sritipsukho, Paskorn, et al.
Publicado: (2023) -
The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial
por: Chantasrisawad, Napaporn, et al.
Publicado: (2023)